AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30390647 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events reported by participants.
Number of subjects: 1919
Study 28557722 — intervention group
Group type: EXPERIMENTAL
Intervention: HS + Preschool Obesity Prevention Series (POPS) + Incredible Years Series (IYS)
Number of subjects: 697
Study 28557722 — intervention group
Group type: EXPERIMENTAL
Intervention: HS + Preschool Obesity Prevention Series (POPS)
Number of subjects: 697
Study 28557722 — intervention group
Group type: COMPARATOR
Intervention: HS
Number of subjects: 697
Study 26244387 — intervention group
Group type: COMPARATOR
Intervention: Control group (tenofovir/emtricitabine + lopinavir/ritonavir)
Number of subjects: 451
Study 26244387 — intervention group
Group type: EXPERIMENTAL
Intervention: ABC/ddI group (abacavir + didanosine + lopinavir/ritonavir)
Number of subjects: 451
Study 26244387 — intervention group
Group type: EXPERIMENTAL
Intervention: DRV group (tenofovir/emtricitabine + darunavir/ritonavir)
Number of subjects: 451
Study 26244387 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 451
Study 26244387 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with baseline viral load at least 100,000 copies/ml
Number of subjects: 451
Study 24089388 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproic acid
Number of subjects: 0
Study 24089388 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethosuximide
Number of subjects: 0
Study 24089388 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 0
Study 24089388 — intervention group
Group type: COMPARATOR
Intervention: Parental assessment
Number of subjects: 0
Study 21345226 — intervention group
Group type: EXPERIMENTAL
Intervention: Real acupuncture
Number of subjects: 354
Study 21345226 — intervention group
Group type: COMPARATOR
Intervention: Placebo acupuncture
Number of subjects: 354
Study 18449593 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimebutine (200 mg)
Number of subjects: 11
Study 18449593 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 16513579 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 160 mg and hydrochlorothiazide (HCTZ) 12.5 mg
Number of subjects: 17242
Study 14510746 — intervention group
Group type: EXPERIMENTAL
Intervention: Raftilin HP (5 or 10 g)
Number of subjects: 0
Study 14510746 — intervention group
Group type: COMPARATOR
Intervention: Lactulose
Number of subjects: 0
Study 14510746 — intervention group
Group type: EXPERIMENTAL
Intervention: Raftilin HP
Number of subjects: 0
Study 14510746 — intervention group
Group type: EXPERIMENTAL
Intervention: Inulin
Number of subjects: 0
Study 11014404 — intervention group
Group type: EXPERIMENTAL
Intervention: Loperamide (16 mg) with quinidine (600 mg)
Number of subjects: 8
Study 11014404 — intervention group
Group type: COMPARATOR
Intervention: Loperamide (16 mg) alone
Number of subjects: 8
Study 9001833 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac (30 mg)
Number of subjects: 60
Study 9001833 — intervention group
Group type: COMPARATOR
Intervention: Placebo (5 mL of normal saline)
Number of subjects: 60
Study 1642346 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 150 micrograms (n = 10)
Number of subjects: 20
Study 1642346 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group, n = 10)
Number of subjects: 20
Study 6601560 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg of 4-aminobenzoic acid (PAB) with meals (240 mg/day)
Number of subjects: 33
Study 6601560 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of 80 mg of PAB
Number of subjects: 33
Study 6601560 — intervention group
Group type: EXPERIMENTAL
Intervention: Various doses of PAB divided throughout the day
Number of subjects: 33
Study 6601560 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg of PAB with meals
Number of subjects: 33
Study 31743342 — intervention group
Group type: EXPERIMENTAL
Intervention: Video abstracts
Number of subjects: 538
Study 31743342 — intervention group
Group type: EXPERIMENTAL
Intervention: Plain language summaries
Number of subjects: 538
Study 31743342 — intervention group
Group type: COMPARATOR
Intervention: Graphical abstracts
Number of subjects: 538
Study 31743342 — intervention group
Group type: COMPARATOR
Intervention: Published abstracts
Number of subjects: 538
Study 31743342 — intervention group
Group type: EXPERIMENTAL
Intervention: All summary types
Number of subjects: 538
Study 28980294 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous N-acetylcysteine (NAC) infusion (50 mg/kg) after induction of anaesthesia, with two additional doses on postoperative days 1 and 2.
Number of subjects: 150
Study 28980294 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo) administered during the same time interval as NAC.
Number of subjects: 150
Study 28980294 — intervention group
Group type: COMPARATOR
Intervention: NAC group vs placebo group regarding hsCRP levels.
Number of subjects: 150
Study 27981301 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vancomycin (125 mg, four times a day) for 12 weeks
Number of subjects: 29
Study 25642527 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centred structured assessment linked to evidence-based treatment algorithms in 15 intervention services.
Number of subjects: 1008
Study 25642527 — intervention group
Group type: EXPERIMENTAL
Intervention: General Health Questionnaire‐12 at 6 months for psychological outcomes.
Number of subjects: 1008
Study 25642527 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional outcomes for patients and outcomes for carers measured through self-completed postal questionnaires at 6 and 12 months.
Number of subjects: 1008
Study 25642527 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness analysis of the intervention.
Number of subjects: 1008
Study 25642527 — intervention group
Group type: EXPERIMENTAL
Intervention: 22-item Longer-term Unmet Needs after Stroke (LUNS) questionnaire.
Number of subjects: 1008
Study 25642527 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative investigation with 22 patients and carers.
Number of subjects: 1008
Study 23726776 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy
Number of subjects: 125
Study 23726776 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal therapy
Number of subjects: 125
Study 23726776 — intervention group
Group type: COMPARATOR
Intervention: Cognitive behavioural therapy / Interpersonal therapy
Number of subjects: 125
Study 22043930 — intervention group
Group type: EXPERIMENTAL
Intervention: Swimming
Number of subjects: 48
Study 22043930 — intervention group
Group type: EXPERIMENTAL
Intervention: Running
Number of subjects: 48
Study 22043930 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling
Number of subjects: 48
Study 22043930 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 48
Study 17965146 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral subthalamic nucleus deep brain stimulation (DBS)
Number of subjects: 23
Study 17965146 — intervention group
Group type: COMPARATOR
Intervention: Medically treated patients with PD
Number of subjects: 23
Study 16035957 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine
Number of subjects: 0
Study 16035957 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 0
Study 16035957 — intervention group
Group type: EXPERIMENTAL
Intervention: VIBES
Number of subjects: 0
Study 16035957 — intervention group
Group type: COMPARATOR
Intervention: HAMD
Number of subjects: 0
Study 12826855 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil at 0.1 microg x kg‐1 x min‐1
Number of subjects: 13
Study 12826855 — intervention group
Group type: EXPERIMENTAL
Intervention: S-ketamine at 5 microg x kg‐1 x min‐1
Number of subjects: 13
Study 12826855 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine at 2 microg/kg for 5 min
Number of subjects: 13
Study 12826855 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 13
Study 11122033 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tazarotene gel with narrowband UVB (311 nm)
Number of subjects: 10
Study 11122033 — intervention group
Group type: COMPARATOR
Intervention: Topical calcipotriol with narrowband UVB (311 nm)
Number of subjects: 10
Study 9382235 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine with 0.1 mg of clonidine
Number of subjects: 60
Study 9382235 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine
Number of subjects: 60
Study 9382235 — intervention group
Group type: COMPARATOR
Intervention: Regular intramuscular morphine
Number of subjects: 60
Study 1397240 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction and consolidation chemotherapy with weekly parenteral vincristine, adriamycin, l‐asparaginase and daily oral prednisone (VAAP)
Number of subjects: 46
Study 1397240 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance therapy for 3 years consisting of daily 6‐mercaptopurine, weekly methotrexate, and monthly intrathecal chemotherapy
Number of subjects: 46
Study 1397240 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug intensification comprising either vincristine, adriamycin and l‐asparaginase (VAA) or cyclophosphamide, vincristine, cytosine arabinoside and prednisone (COAP)
Number of subjects: 46
Study 1397240 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow transplantation
Number of subjects: 46
Study 1397240 — intervention group
Group type: EXPERIMENTAL
Intervention: CNS prophylaxis
Number of subjects: 46
Study 1397240 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment protocol
Number of subjects: 46
Study 3900932 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental nursing intervention group (8 visits over 6 months)
Number of subjects: 0
Study 3900932 — intervention group
Group type: COMPARATOR
Intervention: Conventional care (control group)
Number of subjects: 0
Study 3900932 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental condition
Number of subjects: 0
Study 3900932 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived difficulty in following a diet
Number of subjects: 0
Study 3900932 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of disease
Number of subjects: 0
Study 3900932 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived severity of symptoms
Number of subjects: 0
Study 31601541 — intervention group
Group type: EXPERIMENTAL
Intervention: NYVAC vector followed by NYVAC vector and gp120 Env protein (T1)
Number of subjects: 96
Study 31601541 — intervention group
Group type: EXPERIMENTAL
Intervention: Four doses of NYVAC vector and gp120 Env protein (T2)
Number of subjects: 96
Study 31601541 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of DNA vector followed by two doses of NYVAC vector and gp120 Env protein (T3)
Number of subjects: 96
Study 31601541 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of DNA vector and gp120 Env protein followed by two doses of NYVAC vector and gp120 Env protein (T4)
Number of subjects: 96
Study 31601541 — intervention group
Group type: COMPARATOR
Intervention: Placebo (C1, C2, C3, C4)
Number of subjects: 96
Study 30518042 — intervention group
Group type: EXPERIMENTAL
Intervention: Active image-assisted five-day food records (FR)
Number of subjects: 22
Study 30518042 — intervention group
Group type: COMPARATOR
Intervention: Regular five-day food records (FR)
Number of subjects: 22
Study 30518042 — intervention group
Group type: EXPERIMENTAL
Intervention: Image-assisted food records
Number of subjects: 22
Study 30518042 — intervention group
Group type: COMPARATOR
Intervention: Regular food records
Number of subjects: 22
Study 27314448 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal bevacizumab (400 mg absolute)
Number of subjects: 53
Study 27314448 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 25042605 — intervention group
Group type: EXPERIMENTAL
Intervention: THRIVES intervention (patient report cards, phone text messaging, educational video, coordination of posthospitalization care)
Number of subjects: 400
Study 25042605 — intervention group
Group type: EXPERIMENTAL
Intervention: THRIVES intervention
Number of subjects: 400
Study 22425243 — intervention group
Group type: EXPERIMENTAL
Intervention: Stochastic resonance whole-body vibration (SR‐WBV) training
Number of subjects: 20
Study 22425243 — intervention group
Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 20
Study 20602795 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified constraint-induced movement therapy
Number of subjects: 0
Study 20602795 — intervention group
Group type: COMPARATOR
Intervention: Bimanual occupational therapy
Number of subjects: 0
Study 17580357 — intervention group
Group type: EXPERIMENTAL
Intervention: duloxetine 80 mg/day
Number of subjects: 588
Study 17580357 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 588
Study 15644669 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% mannitol
Number of subjects: 9
Study 15644669 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5% saline/6% dextran solution (HSD)
Number of subjects: 9
Study 12064330 — intervention group
Group type: COMPARATOR
Intervention: 0.8 mg/d phylloquinone for 12 days
Number of subjects: 31
Study 12064330 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 mg/d phylloquinone for 12 days
Number of subjects: 31
Study 12064330 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.0 mg/d phylloquinone for 12 days
Number of subjects: 31
Study 10571498 — intervention group
Group type: EXPERIMENTAL
Intervention: Handgrip test
Number of subjects: 33
Study 10571498 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive 80 degrees head-up tilt
Number of subjects: 33
Study 10571498 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate responsiveness
Number of subjects: 33
Study 10571498 — intervention group
Group type: COMPARATOR
Intervention: Control participants (age- and sex-matched)
Number of subjects: 33
Study 7845827 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone (600 mg)
Number of subjects: 243
Study 7845827 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide (300 mg)
Number of subjects: 243
Study 7845827 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin (1 mg)
Number of subjects: 243
Study 7845827 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 243
Study 2902491 — intervention group
Group type: EXPERIMENTAL
Intervention: Urgent endoscopic retrograde cholangiopancreatography (ERCP) and endoscopic sphincterotomy (ES)
Number of subjects: 121
Study 2902491 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 121
Study 31676910 — intervention group
Group type: EXPERIMENTAL
Intervention: Checking‐in (Graduated extinction protocol)
Number of subjects: 91
Study 31676910 — intervention group
Group type: EXPERIMENTAL
Intervention: Camping‐out (Parental presence maintained)
Number of subjects: 91
Study 31676910 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 91
Study 29448399 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized low-rank factorization
Number of subjects: 0
Study 29448399 — intervention group
Group type: COMPARATOR
Intervention: Truncated singular value decomposition
Number of subjects: 0
Study 28152263 — intervention group
Group type: EXPERIMENTAL
Intervention: Good responders (>15% weight loss)
Number of subjects: 338
Study 28152263 — intervention group
Group type: COMPARATOR
Intervention: Fair responders (5%-10% weight loss)
Number of subjects: 338
Study 28152263 — intervention group
Group type: COMPARATOR
Intervention: Poor responders (<5% weight loss)
Number of subjects: 338
Study 24240577 — intervention group
Group type: EXPERIMENTAL
Intervention: Open Nissen fundoplication (ONF)
Number of subjects: 29
Study 24240577 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic Nissen fundoplication (LNF)
Number of subjects: 29
Study 22574166 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 16
Study 22574166 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 20177030 — intervention group
Group type: EXPERIMENTAL
Intervention: HEC-90 (trastuzumab plus cyclophosphamide and epirubicin 90 mg/m2)
Number of subjects: 120
Study 20177030 — intervention group
Group type: EXPERIMENTAL
Intervention: HEC-60 (trastuzumab plus cyclophosphamide and epirubicin 60 mg/m2)
Number of subjects: 120
Study 20177030 — intervention group
Group type: COMPARATOR
Intervention: EC-90 (epirubicin 90 mg/m2 and cyclophosphamide)
Number of subjects: 120
Study 20177030 — intervention group
Group type: EXPERIMENTAL
Intervention: HEC-60
Number of subjects: 120
Study 20177030 — intervention group
Group type: EXPERIMENTAL
Intervention: HEC-90
Number of subjects: 120
Study 20177030 — intervention group
Group type: COMPARATOR
Intervention: EC-90
Number of subjects: 120
Study 18245119 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux
Number of subjects: 5436
Study 15774776 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiotherapy including fluorouracil and radiation
Number of subjects: 30
Study 14692328 — intervention group
Group type: EXPERIMENTAL
Intervention: Yang Xue Qing Nao Granule (YXQNG)
Number of subjects: 80
Study 14692328 — intervention group
Group type: COMPARATOR
Intervention: Nimedipine plates
Number of subjects: 80
Study 10386423 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine infusion at 'renal dose' (2.5‐4.0 microg/kg per min) for 48 hours
Number of subjects: 40
Study 10386423 — intervention group
Group type: COMPARATOR
Intervention: Untreated controls (Group B)
Number of subjects: 40
Study 8814216 — intervention group
Group type: EXPERIMENTAL
Intervention: 495 mg daily AA supplement (high AA group)
Number of subjects: 20
Study 8814216 — intervention group
Group type: COMPARATOR
Intervention: 5 mg/d of AA (low AA group)
Number of subjects: 20
Study 8814216 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg daily doses of hexadeuterated RRR‐alpha‐tocopherol acetate (d6‐alphaT)
Number of subjects: 20
Study 1481636 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracutaneous sterile water injections
Number of subjects: 10
Study 1481636 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline
Number of subjects: 10
Study 4026048 — intervention group
Group type: COMPARATOR
Intervention: Air
Number of subjects: 8
Study 4026048 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen (40% O2)
Number of subjects: 8
Study 31797581 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin
Number of subjects: 146
Study 31797581 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study 31797581 — intervention group
Group type: EXPERIMENTAL
Intervention: Data reduction techniques
Number of subjects: 146
Study 29186416 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropeptide Y 1.4 mg
Number of subjects: 26
Study 29186416 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropeptide Y 2.8 mg
Number of subjects: 26
Study 29186416 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropeptide Y 4.6 mg
Number of subjects: 26
Study 29186416 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropeptide Y 6.8 mg
Number of subjects: 26
Study 29186416 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropeptide Y 9.6 mg
Number of subjects: 26
Study 29186416 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 26901303 — intervention group
Group type: EXPERIMENTAL
Intervention: In-office bleaching combined with home bleaching (Technique 1)
Number of subjects: 0
Study 26901303 — intervention group
Group type: COMPARATOR
Intervention: Home bleaching only (Technique 2)
Number of subjects: 0
Study 26901303 — intervention group
Group type: EXPERIMENTAL
Intervention: In-office bleaching (part of Technique 1)
Number of subjects: 0
Study 26901303 — intervention group
Group type: COMPARATOR
Intervention: Home bleaching (part of Technique 2)
Number of subjects: 0
Study 26901303 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques (Technique 1 and Technique 2)
Number of subjects: 0
Study 25072915 — intervention group
Group type: EXPERIMENTAL
Intervention: MFIA diagnoses of their lectures plus feedback by an expert observer after winter and summer semester lectures
Number of subjects: 21
Study 25072915 — intervention group
Group type: COMPARATOR
Intervention: MFIA diagnoses only
Number of subjects: 21
Study 22014699 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Number of subjects: 15
Study 22014699 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 15
Study 20863369 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercises (SE)
Number of subjects: 104
Study 20863369 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial extracorporeal shockwave therapy (rESWT)
Number of subjects: 104
Study 17352750 — intervention group
Group type: EXPERIMENTAL
Intervention: Adhesive drape, impermeable to water and air
Number of subjects: 1185
Study 17352750 — intervention group
Group type: COMPARATOR
Intervention: Water- and air-permeable absorbent dressing
Number of subjects: 1185
Study 16286671 — intervention group
Group type: EXPERIMENTAL
Intervention: Astaxanthin (BioAstin; 1732 mg safflower oil; haematococcus algae extract [contains 4 mg astaxanthin and 480 mg lutein], n = 10)
Number of subjects: 20
Study 16286671 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1732 mg safflower oil, n = 10)
Number of subjects: 20
Study 12075481 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongue-stabilizing device (TSD)
Number of subjects: 6
Study 10464888 — intervention group
Group type: COMPARATOR
Intervention: BDP-CFC
Number of subjects: 0
Study 10464888 — intervention group
Group type: EXPERIMENTAL
Intervention: BDP-HFA
Number of subjects: 0
Study 7564937 — intervention group
Group type: EXPERIMENTAL
Intervention: Videotape educational materials
Number of subjects: 82
Study 7564937 — intervention group
Group type: COMPARATOR
Intervention: Booklet educational materials
Number of subjects: 82
Study 1932903 — intervention group
Group type: EXPERIMENTAL
Intervention: Human insulin
Number of subjects: 44
Study 1932903 — intervention group
Group type: COMPARATOR
Intervention: Porcine insulin
Number of subjects: 44
Study 6820075 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid solution containing 3.6% total nitrogen as arginine
Number of subjects: 26
Study 6820075 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid solution containing 10.4% total nitrogen as arginine
Number of subjects: 26
Study 6820075 — intervention group
Group type: EXPERIMENTAL
Intervention: Septic infants
Number of subjects: 26